Malin Corporation PLC Kymab appoints Chief Executive Officer (4662V)
08 April 2019 - 9:25PM
UK Regulatory
TIDM0Y71
RNS Number : 4662V
Malin Corporation PLC
08 April 2019
Malin Corporation plc
("Malin")
Kymab appoints Simon Sturge as Chief Executive Officer
- Malin owns approximately 8% of Kymab, a Malin Priority Asset -
Dublin-Ireland, 8 April 2019: Malin Corporation plc (Euronext
Growth Dublin:MLC), a company investing in highly innovative life
sciences companies, is pleased to note that Kymab, one of Malin's
Priority Assets, has appointed pharmaceutical veteran, Simon
Sturge, as its Chief Executive Officer, effective 1 May 2019.
Simon Sturge will join from Merck KGaA, where he was Executive
Vice President Global Strategy, Business Development & Global
Operations. Previously, he was Chief Operating Officer of Merck
Healthcare, responsible for the company's global commercial and
manufacturing operations. Over the past five years, he has been
responsible for the continued growth in global sales at Merck KGaA,
as well as the commercial launches of products, including
BAVENCIO(R) (anti-PD-L1 avelumab) in solid tumours and MAVENCLAD(R)
(cladribine) for relapsing multiple sclerosis.
"Simon Sturge's appointment as CEO of Kymab strengthens the
company's management team at a crucial time for Kymab when the
company has two clinical-stage lead candidates in development,"
said Jean-Michel Cosséry, Non-Executive Director of Malin and
Malin's Kymab Board designate. "Simon's extensive clinical,
regulatory, business development and commercial knowledge and
experience will greatly benefit the company across all stages of
its maturity. At the same time, we note David Chiswell's
significant contribution and leadership of Kymab over the past many
years and thank him."
Malin owns approximately 8% of Kymab and carried its investment
in Kymab at a fair value estimate of EUR28.7 million at 31 December
2018 under International Private Equity and Venture Capital
Valuation guidelines.
A copy of Kymab's press release is available to view here:
https://www.kymab.com/news-and-events/news/2019/apr/8/kymab-appoints-simon-sturge-ceo/
ENDS
For further information, please contact:
Malin
Jessica Bergin, Director of Investor Relations & External
Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Irish media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in and
supporting highly innovative life sciences companies developing
exceptional science and technology to deliver transformative
outcomes for patients and create significant value for
shareholders. Its purpose is to create shareholder value through
the application of long-term capital and strategic support to its
investee companies to enable them to reach their value potential.
Malin is headquartered and domiciled in Ireland and listed on the
Euronext Growth Dublin. For more information visit
www.malinplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISESSAFFAFUSEFL
(END) Dow Jones Newswires
April 08, 2019 07:25 ET (11:25 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2024 to May 2024
Malin (LSE:0Y71)
Historical Stock Chart
From May 2023 to May 2024